Literature DB >> 17428874

Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.

Krista A Delviks-Frankenberry1, Galina N Nikolenko, Rebekah Barr, Vinay K Pathak.   

Abstract

We recently observed that mutations in the human immunodeficiency type 1 (HIV-1) reverse transcriptase (RT) connection domain significantly increase 3'-azido-3'-deoxythymidine (AZT) resistance up to 536 times over wild-type (WT) RT in the presence of thymidine analog resistance mutations (TAMs). These mutations also decreased RT template switching, suggesting that they altered the balance between nucleotide excision and template RNA degradation, which in turn increased AZT resistance. Several residues in the HIV-1 connection domain contact the primer strand and form an RNase H primer grip structure that helps to position the primer-template at the RNase H and polymerase active sites. To test the hypothesis that connection domain mutations enhanced AZT resistance by influencing the RNase H primer grip, we determined the effects of alanine substitutions in RNase H primer grip residues on nucleoside RT inhibitor resistance in the context of a WT, TAM-containing, or K65R-containing polymerase domain. Ten of the 11 RNase H primer grip mutations increased AZT resistance 20 to 243 times above WT levels in the context of a TAM-containing polymerase domain. Furthermore, all mutations in the RNase H primer grip decreased template switching, suggesting that they reduced RNase H activity. These results demonstrate that mutations in the RNase H primer grip region can significantly enhance AZT resistance and support the hypothesis that mutations in the connection and RNase H domains can increase resistance by altering the RNase H primer grip region, changing interactions between RT and the template-primer complex and/or shifting the balance between the polymerase and RNase H activities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428874      PMCID: PMC1933283          DOI: 10.1128/JVI.02820-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  RNA-dependent DNA polymerase in virions of RNA tumour viruses.

Authors:  D Baltimore
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

2.  RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

Authors:  H M Temin; S Mizutani
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

3.  Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.

Authors:  Dominique Arion; Nicolas Sluis-Cremer; Kyung-Lyum Min; Michael E Abram; Ronald S Fletcher; Michael A Parniak
Journal:  J Biol Chem       Date:  2001-10-29       Impact factor: 5.157

4.  A detailed model of reverse transcription and tests of crucial aspects.

Authors:  E Gilboa; S W Mitra; S Goff; D Baltimore
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

5.  Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity.

Authors:  Jason W Rausch; Daniela Lener; Jennifer T Miller; John G Julias; Stephen H Hughes; Stuart F J Le Grice
Journal:  Biochemistry       Date:  2002-04-16       Impact factor: 3.162

6.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity.

Authors:  John G Julias; Mary Jane McWilliams; Stefan G Sarafianos; W Gregory Alvord; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.

Authors:  Galina N Nikolenko; Evguenia S Svarovskaia; Krista A Delviks; Vinay K Pathak
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 9.  Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).

Authors:  Valérie Goldschmidt; Roland Marquet
Journal:  Int J Biochem Cell Biol       Date:  2004-09       Impact factor: 5.085

10.  Y586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts.

Authors:  Wen-Hui Zhang; Evguenia S Svarovskaia; Rebekah Barr; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

View more
  42 in total

1.  HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Authors:  Atsuko Hachiya; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Xiongying Tu; Krzysztof Palczewski; Yee Tsuey Ong; Zhe Li; Daniel T Griffin; Matthew M Schuckmann; Junko Tanuma; Shinichi Oka; Kamalendra Singh; Eiichi N Kodama; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2012-07-02       Impact factor: 5.157

2.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Authors:  Atsuko Hachiya; Kazuki Shimane; Stefan G Sarafianos; Eiichi N Kodama; Yasuko Sakagami; Fujie Negishi; Hirokazu Koizumi; Hiroyuki Gatanaga; Masao Matsuoka; Masafumi Takiguchi; Shinichi Oka
Journal:  Antiviral Res       Date:  2009-02-21       Impact factor: 5.970

Review 4.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

5.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

6.  N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.

Authors:  Nicolas Sluis-Cremer; Katie Moore; Jessica Radzio; Secondo Sonza; Gilda Tachedjian
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

7.  HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Paul L Boyer; Stephen H Hughes; John M Coffin; Abhay Jere; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

8.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

9.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

10.  Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.

Authors:  Moisés A Árquez; Samara Martín-Alonso; Robert J Gorelick; Walter A Scott; Antonio J Acosta-Hoyos; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.